Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starts & Stops: Respicardia Puts Sleep Apnea Device PAS On Snooze

Executive Summary

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions over the past month. This edition takes a closer look at Respicardia, which has cut short the post-approval study of its implantable sleep apnea device study.

Advertisement

Related Content

Neuronetics Launches Major Registry To Track NeuroStar TMS Outcomes
Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN
Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial
Sorin Gains Distribution Rights, Minority Stake In Respicardia’s remedē Sleep Apnea Device

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT104163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel